Speaker Profile
M.S., CTO, Vincogen corporation
Biography
Alexander G. Lai currently spearheads the development and strategic direction of VincoAI, a pioneering generative AI platform designed to predict peptide-protein binding sequences. His work focuses on transforming drug discovery by integrating high-fidelity in silico modeling to identify therapeutic candidates for complex challenges, including antimicrobial resistance (AMR) and viral proteases.He is a recognized innovator in the biotechnology sector, having been named to the INNO Under 25 list for his contributions to AI-driven precision medicine. His professional history includes delivering key technical presentations at prestigious global forums such as the BIO CEOInvestor Conference and the World AMR Congress.He holds a Bachelors degree in Biology from Penn State University and a Masters degree in Biotechnology from Harvard University. His academic and professional career has been defined by bridging the gap between computational biology and translational medicine to accelerate the delivery of safe, targeted therapeutics.
Talk
In-Silico Drug Discovery, Human-Predictive
Talk Synopsis:In-Silico Drug Discovery, Human-Predictive presents VincoAIs platform, which models physiological protein interactions, reconstructs human signaling pathways, and enables multi-scale in-silico testing of biologics. The talk highlights how this approach reduces preclinical risk, accelerates target validation, and transforms drug discovery months before wet-lab experiments.
AI for Clinical Decision Support Systems Showcase:
Vincogen corporation
Vincogen is a AI biotechnology company developing human-predictive biologics using its proprietary VincoAI platform, which models physiological protein–protein interactions, reconstructs disease signaling pathways, and enables multi-scale in-silico drug discovery across viral, immune, and complex human diseases.
Session Abstract – PMWC 2026 Silicon Valley
"The PMWC 2026 AI for Clinical Decision Support Showcase will provide a 15-30 minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Neurodegenerative
